Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pain, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02719015 2017-11-24

Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT02736123 2017-09-20

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT02661100 2016-12-07

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Phase 1/2 Withdrawn

DermatologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Neoplasms, Small Cell Lung Carcinoma

NCT02862145 2016-09-27

MRX34-102

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT02065466 2016-04-21

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Phase 1/2 Withdrawn

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02452281 2016-01-25

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT01764009 2015-09-11

AIMM

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT01465815 2014-11-19

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Phase 1/2 Withdrawn

Dermatologic

Skin Neoplasms

NCT01531244 2014-07-18

Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT01689870 2014-04-01

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT01340729 2013-04-05

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma, Recurrence, Disease Progression

NCT01101412 2013-02-15

Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

Phase 1/2 Withdrawn

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Immunoglobulin Light-chain Amyloidosis, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Infections, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis, Intraocular Lymphoma

NCT01409187 2012-01-26

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma

Clinical Trials

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

CINDI

UVA-AM-002

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

REO13 Melanoma With of Without GM-CSF

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases

Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

MRX34-102

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

AIMM

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma